The invention relates to methods of (i) predicting cancer patient survival and (ii) determining drug efficacy and/or improvement in a cancer therapy. Methods are based on the absolute lymphocyte count of a blood sample obtained from a cancer patient within 15 days of autologous hematopoietic stem cell transplant. Methods involve treating a cancer patient with a drug, and obtaining an absolute lymphocyte count on a blood sample taken from the cancer patient within 15 days following an autologous hematopoietic stem cell transplant. A lymphocyte count of at least 200 lymphocytes/ mu L is indicative of cancer patient survival of at least 24 months, and is further indicative of the efficacy of the drug and an improved cancer therapy.
申请公布号
WO0238189(A1)
申请公布日期
2002.05.16
申请号
WO2001US46798
申请日期
2001.11.09
申请人
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH;PORRATA, LUIS, F.;MARKOVIC, SVETOMIR, N.